ArticleMedical molecular morphology2026
THBS1 inhibition alleviates inflammatory response by inhibiting TGF-β and NLRP3 inflammasome in experimental murine dry eye.
Article in Medical molecular morphology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Long non-coding RNA FOXD2-AS1 promotes inflammation but suppresses osteogenesis in pulpitis via miR-338-3p/THBS1 axis.Odontology · 2026Article
- Vascular SMC-like CAF-derived THBS1 drives tumor-associated neutrophil recruitment to orchestrate an immunosuppressive microenvironment in gastric cancer.Cell death & disease · 2026Article
- Proteomic and Clinical Characterization of Active vs. Quiescent Pterygium With Elevated Thrombospondin-1.Translational vision science & technology · 2026Article
- Research progress in animal models of dry eye disease: Types, mechanisms, and application prospects.Animal models and experimental medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye is a multifactorial ocular surface disease that may be accompanied by visual impairment and ocular surface damage. Thrombospondin 1 (THBS1) was found to be highly expressed in corneal epithelial cells of dry eye mouse models. Our research aimed at exploring the role and regulatory mechanism of THBS1 in dry eye mouse models. Both eyes of mice with benzalkonium chloride (BAC)-induced dry eye were subconjunctivally injected with the recombinant adeno-associated virus (AAV) vector containing the THBS1 silencing plasmid. Under a slit lamp biomicroscope, the conjunctival irritation including edema, hyperemia, and secretion was scored. Fluorescein staining was performed to evaluate corneal epithelial damage. The conjunctiva tissues were obtained for ELISA, RT-qPCR, histological staining, and western blotting. Dry eye model mice exhibited severe ocular surface damage, reduced tear secretion, conjunctival goblet cell loss, increased conjunctival inflammation, elevated THBS1 expression, and the TGF-β/NLRP3 inflammasome pathway activation. THBS1 silencing ameliorated ocular surface damage, increased tear secretion, attenuated conjunctival goblet cell loss, mitigated conjunctival inflammation, and repressed the TGF-β/NLRP3 inflammasome pathway activation in dry eye mice. THBS1 silencing protects mice against dry eye by inhibiting TGF-β/NLRP3 inflammasome-mediated inflammatory response.
Indexed as
Identifiers
41212269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.